Alan P Skarbnik
机构：Cancer Institute (WIA), Novant Health · ORCID：0000-0002-1276-7546
发表论文 197 篇 · 总被引 5287 次 · h-index 28
代表论文
- Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia (2025 · New England Journal of Medicine · 被引 115)
- Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN (2025 · Blood · 被引 44)
- Consensus recommendations from the 2024 Lymphoma Research Foundation workshop on treatment selection and sequencing in CLL or SLL (2024 · Blood Advances · 被引 22)
- Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma (2025 · Blood · 被引 15)
- Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial (2025 · Journal of Clinical Oncology · 被引 13)
- Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL (2025 · Blood Cancer Journal · 被引 13)